뉴로센스 테라퓨틱스(NRSN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.45 (+2.26%), 시가총액 $0.03B, 52주 범위 $0.69 ~ $2.49.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the
뉴로센스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
뉴로센스 테라퓨틱스의 현재 주가는 $0.45 (+2.26%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
뉴로센스 테라퓨틱스의 시가총액은 약 $0.03B입니다.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and i